Investors head for exits with INSY

Shares of Insys Therapeutics (INSY -15.7%) were down again today on a 4x surge in volume as investors continue to shy away from the controversy surrounding its Subsys marketing practices. Prices are now down 60% from the March 4 high of $57.92.

From other sites
Comments (1)
  • MortyLong
    , contributor
    Comments (191) | Send Message
    Saw this coming from day one, never got the meteoric rise, and the more I read, I don't like. There is a proper use for these medications, I have no doubt but I also am just appalled at the means these companies go to for profits that are at the expense of the very sick. I see a need for this class of medications, I have my personal opinions and know they work but how much profit is enough? The more I read about the "marketing practices" for TIRFs the more I'm disillusioned by management and what I perceive to be the pursuit of money regardless of the costs, tangible and intangible and can we trust sales teams to ensure that it's used responsibly and therefore available for the pain they effectively treat? Do these commissioned teams really understand or care about the ultimate consequences to us all? These people make money when they sell, it's every industry, get those bonuses and bumps, but in pharmaceuticals it is a downright dangerous field to incentivize. How do we know we are getting the safest and right choice? It's a slippery slope and we all lose when money becomes the overriding incentive, IMHO. I hope they see this as an opportunity to turn it around and I hope it's investors see better days.
    15 May 2014, 01:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs